FDA Guides Industry on New Drug Exclusivity Perks
Published Date: 3/4/2026
Notice
Summary
The FDA just dropped a draft guide to help drug makers understand how to get 3-year exclusivity for new clinical studies on their drugs. This means companies can protect their new research from competition for three years, encouraging innovation. If you’re in the drug business, get your comments in by May 4, 2026, or risk missing out on shaping the final rules!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
3‑year exclusivity blocks certain approvals
Under the cited statutory provisions (Hatch‑Waxman/section 505), a granted 3‑year New Clinical Investigation exclusivity means that 505(b)(2) applications and abbreviated new drug applications (505(j)/ANDAs) may not be approved for the exclusivity‑protected conditions of approval for three years after approval.
Draft guide explains 3‑year exclusivity
The FDA published a draft guidance titled “New Clinical Investigation Exclusivity (3‑Year Exclusivity) for Drug Products: Questions and Answers” to help applicants request 3‑year exclusivity under 21 U.S.C. 355(c)(3)(E)(iii)-(iv) and 355(j)(5)(F)(iii)-(iv). The guidance explains the statutory and regulatory eligibility criteria, how FDA will make eligibility determinations, recommends content/format in a Q&A style, and invites comments by May 4, 2026.
Template provided with no extra paperwork
The draft guidance includes a model template (in the Appendix) that FDA recommends applicants use to request New Clinical Investigation (3‑year) exclusivity. FDA tentatively concludes that providing the template “adds no further information collection requirements and imposes no further burden” beyond existing requirements covered by OMB control number 0910-0001.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2026-04290, Proposed Collection; Comment Request
The Pentagon Force Protection Agency wants your thoughts on a new info collection about Pentagon access and visitor management. If you deal with Pentagon entry or visits, this could affect you. They’re asking for comments by May 4, 2026, to make sure the process is clear, useful, and not a hassle—no extra costs expected.
Next: 2026-04292, Proposed Collection; Comment Request
The Pentagon Force Protection Agency wants your thoughts on updating some forms they use to recruit and check the health and fitness of their team. If you’re involved or interested, you can comment until May 4, 2026. This update aims to make the forms clearer and easier to fill out, with no extra costs expected.